TARGET AUDIENCE
This activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows and other healthcare providers involved in the treatment of renal cell cancer.

OVERVIEW OF ACTIVITY
Renal cell carcinoma (RCC) is by far the most common primary tumor known to develop within the kidney and renal pelvis. Although RCC may present as diverse histologic subtypes, more than 85% of these are clear cell cancers. Historically, treatment of advanced clear cell RCC, which is resistant to conventional chemotherapeutics, had been limited to cytokine immunotherapy. Beginning in 2005, this paradigm shifted rapidly and dramatically, culminating in the FDA approval of 7 new therapeutic agents or regimens for advanced-stage disease. Thus, practicing oncologists must now maintain current knowledge of the benefits and risks of the multiple acceptable treatment approaches. To bridge the gap between research and patient care, this program features a case-based roundtable discussion with leading investigators to assist medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of RCC with the formulation of up-to-date clinical management strategies.

LEARNING OBJECTIVES

• Identify patient characteristics that may help to distinguish the individualized utility of cytoreductive nephrectomy in the era of effective targeted therapies for metastatic RCC (mRCC).
• Recall criteria for identification of patients with asymptomatic mRCC who may be suitable for watchful waiting or treatment holidays, and apply these to therapeutic decision-making.
• Educate patients with mRCC about the benefits and risks of multikinase VEGF tyrosine kinase inhibitors, mTOR inhibitors and VEGF monoclonal antibody therapy.
• Recommend supportive measures to enhance the tolerability of targeted therapeutic agents for RCC such as the use of dose reductions and schedule changes.
• Apply the results of existing and emerging clinical research to the evidence-based selection of front-line and subsequent therapy for mRCC.
• Recall the scientific rationale for and efficacy of approved and novel investigational immunotherapeutic agents demonstrating activity in RCC.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CME credit is no longer available for this issue

CREDIT DESIGNATION STATEMENT

CME credit is no longer available for this issue

HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component. The participant should watch the video.

CME credit is no longer available for this issue

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

Robert A Figlin, MD
Steven Spielberg Family Chair in Hematology Oncology
Professor of Medicine and Biomedical Sciences
Director, Division of Hematology Oncology
Deputy Director
Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, California

Advisory Committee: Galena Biopharma, Onyx Pharmaceuticals Inc, Pfizer Inc; Contracted Research: Bristol-Myers Squibb Company, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Pfizer Inc.

Thomas E Hutson, DO, PharmD
Director, GU Oncology Program
Co-Director, GU Center of Excellence
Texas Oncology, PA
Charles A Sammons Cancer Center
Baylor University Medical Center
Professor of Medicine, Texas A&M Health Science Center College of Medicine
Co-Chair of GU Research, US Oncology
Dallas, Texas

Advisory Committee and Consulting Agreements: Bayer HealthCare Pharmaceuticals, GlaxoSmithKline, Pfizer Inc; Contracted Research: GlaxoSmithKline, Pfizer Inc; Speakers Bureau: Bayer HealthCare Pharmaceuticals, GlaxoSmithKline, Pfizer Inc, Sanofi.

David F McDermott, MD
Associate Professor of Medicine
Harvard Medical School
Director, Biologic Therapy and Cutaneous Oncology Programs
Beth Israel Deaconess Medical Center
Leader, Kidney Cancer Program
Dana-Farber Harvard Cancer Center
Boston, Massachusetts

Consulting Agreements: Bristol-Myers Squibb Company, Genentech BioOncology, GlaxoSmithKline, Pfizer Inc, Roche Laboratories Inc.

Robert J Motzer, MD
Medical Oncologist
Memorial Sloan-Kettering Cancer Center
New York, New York

Consulting Agreements: Genentech BioOncology, Pfizer Inc; Contracted Research: Bristol-Myers Squibb Company, Eisai Inc, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Pfizer Inc.

David I Quinn, MBBS, PhD
Medical Director, Norris Cancer Hospital and Clinics
Leader, Developmental Therapeutics
Head, GU Cancer Section
Division of Cancer Medicine and Blood Diseases
USC/Norris Comprehensive Cancer Center
Los Angeles, California

Advisory Committee: Amgen Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Dendreon Corporation, Genentech BioOncology, Janssen Pharmaceuticals Inc, Medivation Inc, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Pfizer Inc, Prometheus Laboratories Inc, Teva Oncology, Veridex LLC; Paid Research: Millennium: The Takeda Oncology Company, Sanofi; Other Remunerated Activities: Medivation Inc, Teva Oncology.

Walter Stadler, MD
Fred C Buffett Professor of Medicine and Surgery
Interim Section Chief, Hematology/Oncology
University of Chicago
Chicago, Illinois

Advisory Committee: Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation; Consulting Agreements: Genentech BioOncology, Pfizer Inc; Contracted Research: Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, GlaxoSmithKline, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi.

MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation and Prometheus Laboratories Inc.

Hardware/Software Requirements:
A high-speed Internet connection

A monitor set to 1280 x 1024 pixels or more

Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later

Adobe Flash Player 10.2 plug-in or later

Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: October 2013
Expiration date: October 2014